---
title: 'Vice President, Information Technology at REGENXBIO'
canonical: 'https://feeny.ai/job/vice-president-information-technology-regenxbio-rockville-ekqdx4dtve6s'
type: 'job'
last_seen: '2026-11-02'
---

# Vice President, Information Technology at REGENXBIO

- **Company:** REGENXBIO
- **Location:** Rockville, MD
- **Employment:** full-time
- **Work type:** hybrid
- **Posted:** 2026-10-01
- **Last confirmed live:** 2026-11-02
- **Apply:** https://jobs.lever.co/regenxbio/f5252a10-dcfc-4955-8a0d-a18488e00294

## Job description

Since our founding in 2009, REGENXBIO has pioneered what’s possible in gene therapy. Today, we are advancing a pipeline of gene therapies designed to improve the lives of patients facing serious rare and retinal diseases and preparing to bring innovative new medicines to patients. Our work is fueled by purpose and urgency because every day matters to patients and their families. At REGENXBIO, you’ll find meaningful opportunities to grow, collaborate, and contribute to the advancement of potentially transformative gene therapies. Together, our talented team is working to make a meaningful difference for patients and their families. What we do matters.

The Opportunity The Vice President, Information Technology (IT) is the senior technology leader for REGENXBIO, responsible for setting and executing an enterprise IT strategy that enables corporate priorities and prepares the organization for continued growth and commercialization. Reporting to the Chief Financial Officer, this strategic and hands-on leader serves as a trusted advisor to executive and functional leaders and oversees the full IT portfolio, including enterprise applications, infrastructure and cloud services, cybersecurity, data and analytics, digital enablement, end-user services, and technology vendor partnerships. The VP, IT will also guide the responsible adoption of automation, artificial intelligence, and other emerging technologies to simplify work, strengthen decision-making, and create measurable business value.

## How You’ll Contribute

- Technology Strategy & Commercialization Readiness
- Develop and execute a multi-year enterprise IT strategy and roadmap aligned with REGENXBIO's clinical development priorities, commercialization plans, operating model, and growth.
- Advise executive and functional leaders on technology investments, risks, tradeoffs, and sequencing required to move from a clinical-stage company to a commercial organization.
- Translate commercialization milestones into a sequenced technology, data, and process roadmap with clear dependencies, owners, and readiness criteria.
- Lead enterprise technology readiness for commercialization, including scalable capabilities for manufacturing and supply chain, Quality, Regulatory, Medical Affairs, commercial operations, patient services, Finance, and Human Resources as business needs evolve.
- Establish technology governance, decision rights, architecture standards, portfolio priorities, and performance measures that support launch milestones, accountability, and execution.
- Enterprise Technology & Service Delivery
- Lead the enterprise technology portfolio, including cloud and infrastructure, networks, identity and access, enterprise and scientific applications, collaboration tools, end-user computing, and IT service delivery.
- Establish and lead enterprise IT portfolio and project management governance, including investment prioritization, resource planning, delivery methodologies, project controls, risk and dependency management, executive reporting, and benefits realization.
- Ensure technology services are reliable, resilient, scalable, well documented, and designed around a strong employee and customer experience.
- Select, implement, integrate, and optimize fit-for-purpose solutions; simplify the application portfolio and design integrations and data flows that can scale for commercial operations.
- Lead the Business Analysis capability, establishing standards and practices for business process analysis, requirements management, solution evaluation, process design, and translation of business needs into scalable technology solutions.
- Establish service levels, operational metrics, and continuous improvement practices that strengthen system performance, responsiveness, and user experience.
- Cybersecurity, Risk & Compliance
- Set and maintain the enterprise cybersecurity strategy and information security management approach, including policies, controls, monitoring, awareness, and risk management.
- Establish and direct the IT strategy and governance framework including GxP-regulated systems, ensuring technology capabilities, processes, and controls meet applicable regulatory, quality, data integrity, privacy, public company, and information security requirements throughout the system lifecycle.
- Ensure effective lifecycle governance for regulated systems, including risk assessment, validation planning and execution, change control, periodic review, data integrity, supplier oversight, and system retirement.
- Lead and maintain REGENXBIO’s information security management system and ISO 27001 responsibilities.
- Lead technology business continuity, disaster recovery, incident preparedness, and technology risk management.
- Partner with Legal, Quality, Compliance, Finance, and business leaders to maintain appropriate governance for data, systems, access, and technology-enabled processes.
- Data, Digital Enablement & Innovation
- Build governed data, integration, analytics, and reporting capabilities that provide trusted information for clinical, operational, and commercial decisions.
- Identify and implement practical uses of automation, artificial intelligence, and other emerging technologies that improve productivity and business outcomes.
- Establish responsible governance for AI-enabled solutions and lead adoption so new tools and processes deliver sustained value.
- Vendor, Financial & Portfolio Management
- Own IT budgeting, forecasting, investment planning, and resource allocation, with a focus on business value, scalability, risk, and cost effectiveness.
- Lead vendor selection, contracting support, performance management, and strategic relationships with technology providers, consultants, and managed service partners.
- Maintain internal ownership of technology architecture, standards, security, data, and outcomes while using external partners where they provide the greatest value.
- Leadership & Organization
- Build, lead, coach, and develop a high-performing IT organization with clear accountabilities, strong technical and business capabilities, and a customer-focused service mindset.
- Set clear priorities and outcomes, assign ownership, and hold the team and partners accountable for delivery.
- Foster a collaborative culture that supports innovation, learning, direct communication, and continuous improvement while balancing speed, quality, risk, and compliance.
- Communicate complex technology topics in clear business terms and build strong partnerships across functions and levels.
- REGENXBIO employees must embody the company's core values by collaborating, building strong relationships, and communicating clearly to meet shared objectives.

## What You’ll Bring

- Bachelor's degree in Information Technology, Computer Science, Engineering, Business, or a related field required; advanced technical degree or MBA preferred.
- 15+ years of progressive technology leadership experience, including enterprise-wide accountability in a high-growth or highly regulated organization.
- Experience leading IT in biotechnology, pharmaceuticals, life sciences, or healthcare; experience preparing a clinical-stage company for commercialization or scaling a commercial biotechnology organization strongly preferred.
- Broad technology leadership experience spanning enterprise applications, cloud and infrastructure, cybersecurity, data and analytics, integration, end-user services, and IT operations.
- Demonstrated success building and executing technology roadmaps, modernizing systems and processes, and scaling IT capabilities through significant growth and change.
- Strong understanding of regulated technology environments, including FDA regulated environments, system validation, data integrity, cybersecurity, privacy, business continuity, and disaster recovery. Experience with ISO 27001 and public-company or Sarbanes-Oxley requirements is required.
- Experience establishing commercialization-ready technology and data capabilities across functions such as Manufacturing and Supply Chain, Quality, Regulatory, Medical Affairs, Commercial Operations, Patient Services, and Finance.
- Demonstrated ability to implement data, analytics, automation, and AI-enabled capabilities responsibly, including master data management and business intelligence.
- Experience managing technology budgets, complex vendor relationships, managed service providers, and build-versus-buy decisions.
- Proven people leader with experience building high-performing teams, developing talent, creating accountability, and leading through organizational change.
- Strong business acumen and executive presence, with the ability to build relationships, translate complex technical topics into clear recommendations, and influence technical and non-technical stakeholders.

## What You Can Expect

At REGENXBIO, we're committed to fostering an environment where people can do meaningful work, grow professionally, and make an impact. Our core values - trust, accountability, perseverance, and innovation - drive everything we do.

We offer a comprehensive and competitive benefit and compensation package that includes market-competitive salaries, an annual bonus program, education assistance, paid caregiver leave, a retirement plan with employer match, stock options at all levels, summer hours, and more. The estimated compensation range for this role is $285,000-$406,000 annually. The actual salary offered to the final candidate depends on factors such as relevant work experience, skills, education, and years of experience.

## About REGENXBIO

## Company Overview
- **One-liner**: REGENXBIO is a clinical-stage biotechnology company developing one-time gene therapies for rare and retinal diseases using its proprietary AAV vector platform.
- **Entity Type**: Public (NASDAQ: RGNX)
- **Headquarters**: Rockville, Maryland, United States
- **Founded**: 2008 (founded as a company; operations began in 2009)
- **Founders**: Not publicly listed as individual founders; the company was spun out from the gene therapy research of the University of Pennsylvania and licensed its NAV Technology Platform from the university.

## Core Business
- **Primary industry**: Biotechnology – Gene Therapy (AAV-based)
- **Target customers**: B2B (pharma partners like AbbVie, Nippon Shinyaku) and B2G (regulatory agencies, clinical trial sites); ultimate customers are patients with rare and retinal diseases (Duchenne muscular dystrophy, MPS I, MPS II, wet AMD, diabetic retinopathy).
- **Mission or purpose statement**: “To improve lives through the curative potential of gene therapy.” [regenxbio.com](https://www.regenxbio.com/culture-careers/)

## Products & Services
- **NAV® Technology Platform**: Proprietary AAV vector gene delivery platform (including AAV8 and AAV9) used for internal programs and licensed to partners (e.g., Novartis for ZOLGENSMA®).
- **ABBV-RGX-314** (in collaboration with AbbVie): Investigational one-time gene therapy for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR). In pivotal clinical trials.
- **RGX-202** (Duchenne muscular dystrophy): Phase I/II/III AFFINITY DUCHENNE® trial; pivotal phase expected to support BLA submission in 2026 using accelerated approval pathway. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa)
- **RGX-121** (MPS II – Hunter syndrome): In partnership with Nippon Shinyaku; late-stage development.
- **RGX-111** (MPS I – Hurler syndrome): In partnership with Nippon Shinyaku; clinical development.
- **Manufacturing**: In-house cGMP production facility (REGENXBIO Manufacturing Innovation Center – RMIC) in Rockville, MD, operational since mid-2022.

## Market Standing
- **Valuation/Market Cap**: $447.8 million (as of recent data). [linkedin.com](https://linkedin.com/company/regenx)
- **Key Metric**: Annual Revenue $170.4 million (primarily from license and collaboration revenue). [linkedin.com](https://linkedin.com/company/regenx)
- **Notable Investors/Partners**:
    - AbbVie (collaboration for ABBV-RGX-314)
    - Nippon Shinyaku (partnerships for RGX-121 and RGX-111)
    - Novartis (licensee for ZOLGENSMA® using NAV vectors)
- **Growth Signals**:
    - Headcount: 296 employees (+1.3% YoY). [linkedin.com](https://linkedin.com/company/regenx)
    - BLA submission for RGX-202 targeted for 2026.
    - RMIC facility operational since 2022, enabling scalable clinical and commercial manufacturing.
    - Scholarly output: 160 works, 7,337 citations, field-weighted citation impact of 2.6 (highly influential). [linkedin.com](https://linkedin.com/company/regenx)

## Competitive Advantages
- **Proprietary NAV Technology Platform**: Exclusive rights to a large portfolio of AAV vectors (including AAV8 and AAV9), the foundation for multiple approved and investigational gene therapies. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa)
- **End-to-end capabilities**: Integrated in-house R&D, preclinical development, clinical development, and cGMP manufacturing.
- **Proven platform**: Thousands of patients have been treated with AAV vectors from the NAV platform (including via Novartis’ ZOLGENSMA®).
- **Late-stage pipeline**: Multiple programs in pivotal or near-pivotal trials (RGX-202, ABBV-RGX-314) with clear regulatory pathways.

## Strategic Focus
- **Near-term**: Advance RGX-202 toward BLA submission in 2026; continue pivotal trials for ABBV-RGX-314 in wet AMD and diabetic retinopathy.
- **Long-term**: Expand pipeline in retinal, neuromuscular, and neurodegenerative diseases; leverage RMIC for commercial-scale manufacturing; deepen partnerships with AbbVie and Nippon Shinyaku.
- **Platform expansion**: Ongoing research to expand NAV vector capabilities and develop new AAV-based therapies.

## Why Work Here
- **Mission-driven culture**: “Patient-focused, driven by results, fosters collaboration.” Core values emphasize accountability, innovation, and serving patients with limited therapeutic options. [regenxbio.com](https://www.regenxbio.com/culture-careers/)
- **Impactful work**: Opportunity to work on one-time gene therapies that could fundamentally alter the course of devastating diseases.
- **Growth & stability**: Public company with late-stage pipeline, strong partnerships, and a clear path to commercialization.
- **Location & facilities**: Headquarters in Rockville, MD, with a state-of-the-art cGMP manufacturing facility (RMIC) on site.
- **Work policy**: Not explicitly stated as remote/hybrid; positions appear to be on-site (based on job listings in Rockville and field-based Medical Science Liaison roles).
- **Perks**: Comprehensive and competitive benefits for employees and families. [regenxbio.com](https://www.regenxbio.com/culture-careers/)
- **Engineering & science culture**: High scholarly output and citation impact; emphasis on cross-functional collaboration between research, manufacturing, and clinical teams.
- **Recruitment note**: REGENXBIO warns of fraudulent job offers; all applications go through their official Lever portal. [regenxbio.com](https://www.regenxbio.com/culture-careers/)

## Sources
1. [regenxbio.com – Culture & Careers](https://www.regenxbio.com/culture-careers/)
2. [linkedin.com – REGENXBIO company page](https://linkedin.com/company/regenx)
3. [ir.regenxbio.com – 10-K Filing (Business Overview)](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa)
4. [ir.regenxbio.com – Investor Overview](https://ir.regenxbio.com/investor-overview)
5. [jobs.lever.co – REGENXBIO careers](https://jobs.lever.co/regenxbio)

## Other roles at REGENXBIO

- [Lead Integration Developer](https://feeny.ai/job/lead-integration-developer-regenxbio-rockville-x52a6y2n5b0w) — Rockville, MD
- [VP, Global Rare Disease Franchise](https://feeny.ai/job/vp-global-rare-disease-franchise-regenxbio-remote-zw2996mdrwy4)
- [People Intern](https://feeny.ai/job/people-intern-regenxbio-rockville-mq2tm3vcjxe7) — Rockville, MD
- [Associate Director, Regulatory Affairs](https://feeny.ai/job/associate-director-regulatory-affairs-regenxbio-rockville-1grfyr3vz4sy) — Rockville, MD
- [Head of Sales, Rare Disease](https://feeny.ai/job/head-of-sales-rare-disease-regenxbio-remote-qhp7fgpvfvzm)
- [Associate Director, People Business Partner](https://feeny.ai/job/associate-director-people-business-partner-regenxbio-rockville-fmx3gbzx681y) — Rockville, MD
- [Director, Commercial Data, Advanced Analytics & Forecasting](https://feeny.ai/job/director-commercial-data-advanced-analytics-forecasting-regenxbio-remote-88y6fvc5kv5j)
- [Associate Director, Rare Disease Product Marketing](https://feeny.ai/job/associate-director-rare-disease-product-marketing-regenxbio-rockville-r2p05phcvmx8) — Rockville, MD
- [Senior Director, Global Program Development Lead - DMD/Neuromuscular](https://feeny.ai/job/senior-director-global-program-development-lead-dmd-neuromuscular-regenxbio-xbereeg0zrc8) — Rockville, MD
- [Senior Director/Director, Medical Science Liaisons (Neuromuscular/DMD)](https://feeny.ai/job/senior-director-director-medical-science-liaisons-neuromuscular-dmd-regenxbio-aeca83gb75e2)